

Un-Audited Financial Results of Quarter Ended Sep . 2013
30-09-2013 of M/s. Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

Un-AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 30th September , 2013

PART I							Rs. In Lacs
		(Rs. in Lakhs)					
Particulars		Quarter Ended			Hald Year Ended		Year Ended
		Sep-13	Jun-13	Sep-12	Sep-13	Sep-12	Mar-13
(Refer Notes Below)		Reviwed	Reviwed	Reviwed	Reviwed	Reviwed	(Audited)
1	Income from operations						
	(a) Net sales/ income from operations (Net of Excise duty)	91.17	87.72	67.95	178.88	186.61	439.65
	(b) Other operating income			2.68		5.83	161.43
	Total income from operations (net)	91.17	87.72	70.63	178.88	192.44	601.09
2	Expenses						
	(a) Cost of materials consumed	61.54	51.72	24.45	113.26	63.68	159.30
	(b) Purchases of stock-in-trade	20.86	23.72	38.69	44.58	99.01	240.97
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(13.25)	(12.25)	(10.33)	(25.50)	(12.31)	(24.73)
	(d) Employee benefits expense	6.02	6.30	2.58	12.32	6.72	43.39
	(e) Depreciation and amortisation expense	5.25	5.25	4.79	10.50	9.54	21.10
	(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	5.22	5.71	5.78	10.93	14.76	81.08
	Total expenses	85.64	80.45	65.96	166.08	181.40	521.11
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	5.53	7.27	4.67	12.80	11.04	79.88
4	Other income	1.05	1.05	1.05	2.10	2.10	6.20
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	6.58	8.32	5.72	14.89	13.14	86.17
6	Finance costs	3.75	3.75	2.30	7.50	4.60	19.16
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	2.83	4.57	3.42	7.39	8.54	67.01
8	Exceptional items						
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	2.83	4.57	3.42	7.39	8.54	67.01
10	Tax expense						12.77
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	2.83	4.57	3.42	7.39	8.54	54.24
12	Minority interest *						
13	Net profit/(loss) after taxes minority Interest and share of profit/ (loss) of associates (13+14+ 15)	2.83	4.57	3.42	7.39	8.54	54.24
14	Paid-up equity share capital	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
	(Face Value of the Share shall be indicated)	10	10	10	10	10	10
15	Reserve excluding Revaluation Reserves						
16.I	Earnings per share (before extraordinary items)						-1274.37
	(of Rs. 10/- each) (not annualised):						
	(a) Basic	0.0017	0.0028	0.0021	0.0045	0.0052	0.0333
	(b) Diluted						

See accompanying note to the financial results

|| 2 ||

PART II

	Particulars	Sep-13	Jun-13	Sep-12	Sep-13	Sep-12	Mar-13
		Reviwed	Reviwed	Reviwed	Reviwed	Reviwed	(Audited)
A	PARTICULARS OF SHAREHOLDING						
	1 Public shareholding						
	- Number of shares	8655100	8655100	8655100	8655100	8655100	8655100
	- Percentage of shareholding	53.18	53.18	53.18	53.18	53.18	53.18
	2 Promoters and Promoter Group Shareholding **						
	a) Pledged / Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non - encumbered						
	- Number of shares	7618700	7618700	7618700	7618700	7618700	7618700
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	46.82	46.82	46.82	46.82	46.82	46.82


	Particulars	3 months ended
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	Nil

Notes

1. Above Unaudited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 14th November 2013
2. Figures have been regrouped wherever necessary including as per revised schedule VI
3. The Statuary auditors have carried out a limited review of the result for quarter ended 30th Sep- 2013

Date : 14.11.2013

Place : Indore



RAMESH SHAH
MANAGING DIRECTOR

BIOFIL CHEMICALS & PHARMACE


Segmentwise Revenue, Results an Capital Employed for half year ended 30th Sep 2013
(Under Clause 41 Listing Agreement)

Rs. In lacs

S.No.	Segment Revenue	Quarter Ended				31 March
		Sep 30 , 2013	June 30 , 2013	Sep 30 , 2012	Sep 30 , 2013	
		Reviewed	Reviewed	Reviewed	Reviewed	Audited
1	Segment Revenue					
	Pharma Unit	20.04	16.46	43.84	36.50	403.67
	Chemicals Division	46.80	56.37	22.64	103.17	147.30
	Plastic Division	23.84	14.90	4.14	38.74	50.11
	Other	1.05	1.05	1.05	2.10	6.12
	Gross Turnover	91.74	88.78	71.68	180.52	607.21
2	Segment Results					
	Pharma Unit	(1.23)	(1.25)	3.50	(2.48)	104.99
	Chemicals Division	9.27	11.82	3.74	21.09	(7.40)
	Plastic Division	(1.46)	(2.25)	(1.53)	(3.71)	(9.36)
	Other	0.00	0.00	0.00	0.00	(2.24)
	Total Segment Profit Before Tax	6.58	8.32	5.71	14.90	85.99
	Interest Income	0.00	0.00	-	-	0.08
	Interest Expenses	3.75	3.75	2.30	7.50	19.05
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	2.83	4.57	3.40	7.39	67.01
	Provision for current tax	0.00	0.00	-	-	(12.77)
	Profit After Tax	2.83	4.57	3.40	7.39	54.24
3	Capital Employed					
	(Segment Assets- Segment Liabilities)					
	Pharma Unit	246.45	46.01	(165.78)	246.45	(71.87)
	Chemicals Division	554.49	732.09	733.59	554.49	661.18
	Plastic Division	(15.96)	(39.55)	73.36	(15.96)	75.31
	Other	(51.55)	(3.86)	79.80	(51.55)	84.40
	Total Capital Employed	733.42	734.69	720.97	733.42	749.02

DATE : 14-11-2013
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.



RAMESH SHAH
MANAGING DIRECTOR

BIOFIL CHEMICALS & PHARMACEUTICALS Ltd.
UN-AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30-09-2013

(In Rs.)

Standalone / Consolidated Statement of Assets and Liabilities		Un-audited	Audited
Particulars		30/09/2013	31/03/2013
A	EQUITY & LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	162738000	162738000
	(b) Reserves & Surplus	-89396315	-89113315
	(c) Money received against share warrants		
	Sub-total - Shareholders' funds	73341685	73624685
2	Share application money pending allotment		
3	Minority interest *		
4	Non-current liabilities		
	(a) Long-term borrowings		
	(b) Deferred tax liabilities (net)		
	(c) Other long-term liabilities		
	(d) Long-term provisions		
	Sub-total Non-current liabilities		
5	Current liabilities		
	(a) Short-term borrowings	29491115	27945486
	(b) Trade payables	30509330	31071338
	(c) Other current liabilities	39071	39071
	(d) Short-term provisions	840000	2253234
	Sub-total Current liabilities	60879516	61309129
	TOTAL - EQUITY AND LIABILITIES	134221201	134933814
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	Tangible Assests	90749882	91712022
	(b) Goodwill on consolidation *		
	(c) Non-current investments		
	(d) Deferred tax assets (net)		
	(e) Long-term loans and advances		
	(f) Other non-current assets		
	Sub-total - Non-current assets	90749882	91712022
2	Current assets		
	Current investments		
	Inventories	5773725	3223725
	Trade receivables	31705054	33371194
	Cash and cash equivalents	1677501	1327114
	Short-term loans and advances	2921189	3905909
	Other current assets	1393850	1393850
	Sub-total - Current assets	43471319	43221792
	TOTAL - ASSETS	134221201	134933814

DATE : 14.11.2013

PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.